2024
Cardiovascular Events in Adults with Type 2 Diabetes and ASCVD Initiating Once-Weekly Semaglutide vs DPP-4is in the USA
Inzucchi S, Tan X, Liang Y, Yedigarova L, Xie L, de Havenon A. Cardiovascular Events in Adults with Type 2 Diabetes and ASCVD Initiating Once-Weekly Semaglutide vs DPP-4is in the USA. Diabetes Therapy 2024, 1-17. PMID: 39688779, DOI: 10.1007/s13300-024-01678-4.Peer-Reviewed Original ResearchHealth care resource utilizationAtherosclerotic cardiovascular diseaseDPP-4i usersDPP-4isGLP-1 RAsOnce-weekly semaglutideMedical costsType 2 diabetesDPP-4iDecreased risk of strokeRisk of cardiovascular outcomesCardiovascular eventsOnce-weekly GLP-1 RAsPeptide 1 receptor agonistsTotal medical costsDipeptidyl peptidase 4 inhibitorsOccurrence of cardiovascular eventsHigh-risk patientsRisk of strokeObservational cohort analysisData Mart DatabaseOutpatient visitsDecreased riskSemaglutide treatmentBaseline characteristics
2023
Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease
Tan X, Liang Y, Rajpura J, Yedigarova L, Noone J, Xie L, Inzucchi S, de Havenon A. Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease. Cardiovascular Diabetology 2023, 22: 319. PMID: 37985992, PMCID: PMC10662529, DOI: 10.1186/s12933-023-02051-8.Peer-Reviewed Original ResearchConceptsHealth care resource utilizationAtherosclerotic cardiovascular diseaseGLP-1 RAsCause health care resource utilizationPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsDPP-4i usersPeptidase-4 inhibitorsMyocardial infarctionMedical costsDPP-4iIschemic strokeReceptor agonistCardiovascular diseaseGlucagon-like peptide-1 receptor agonistsWeekly glucagon-like peptide-1 receptor agonistWeekly GLP-1 RAsCause ER visitsCause hospitalization costsCause medical costsNew adult usersClinical cardiovascular outcomesObservational cohort studyType 2 diabetesCause outpatient visits791-P: Comparing the Real-World Effects of Once-Weekly GLP-1 RAs and DPP-4 Inhibitors on Ischemic Stroke and Myocardial Infarction in Individuals with T2D and ASCVD
TAN X, LIANG Y, RAJPURA J, YEDIGAROVA L, NOONE J, XIE L, DE HAVENON A. 791-P: Comparing the Real-World Effects of Once-Weekly GLP-1 RAs and DPP-4 Inhibitors on Ischemic Stroke and Myocardial Infarction in Individuals with T2D and ASCVD. Diabetes 2023, 72 DOI: 10.2337/db23-791-p.Peer-Reviewed Original ResearchAtherosclerotic cardiovascular diseaseGLP-1 RAsMyocardial infarctionDPP-4iIschemic strokeCardiovascular eventsNovo NordiskGlucagon-like peptide-1 receptor agonistsWeekly glucagon-like peptide-1 receptor agonistMajor adverse cardiovascular eventsPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsRisk of MINew adult usersAdverse cardiovascular eventsRetrospective cohort studyPeptidase-4 inhibitorsDPP-4 inhibitorsType 2 diabetesReal-world evidenceDrug discontinuationBaseline characteristicsCohort studyOptum ClinformaticsReceptor agonist